Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

BD GeneOhm Cdiff molecular assay receives CE mark

BD Diagnostics : 07 July, 2008  (New Product)
BD Diagnostics, a segment of BD (Becton, Dickinson and Company), has received the CE marking of the BD GeneOhm Cdiff molecular assay for the rapid diagnosis of patients with Clostridium difficile infection (CDI).
The Assay is the first CDI diagnostic test that offers sensitivity, simplicity and speed in one test procedure. BD has also submitted this Assay to the US Food and Drug Administration for clearance.

CE marked under the European In Vitro Diagnostics Directive for the identification of toxigenic Clostridium difficile directly from stool specimens, the BD GeneOhm Cdiff Assay targets the toxin B gene, found in toxigenic Clostriduim difficile strains. It is the only CDI diagnostic test that combines high Assay sensitivity with a rapid turnaround time of less than two hours, facilitating earlier appropriate treatment of patients suffering from CDI and earlier implementation of Infection control interventions to prevent transmission of Clostridium difficile to other patients. Until now, rapid diagnosis of CDI has been difficult since traditional methods consist of immunoassays, which lack sufficient sensitivity, and traditional ‘gold standard’ tissue culture cytotoxicity methods, which are difficult to perform and require several days to yield results.

'The BD GeneOhm Cdiff Assay provides a simple and rapid stool test with excellent sensitivity and specificity that allows same-day identification of toxigenic Clostridium difficile,' said Thomas Davis, MD, PhD, professor, pathology and laboratory medicine, Clarian Pathology Laboratory. 'This test should improve patient care because it effectively eliminates the need for multiple screening and confirmatory assays, speeds up reporting and helps avoid unnecessary antibiotic use.'

'CDI poses a significant challenge for healthcare facilities around the world,' said Jamie Condie, vice president and general manager, BD Diagnostics - GeneOhm. 'The introduction of the BD GeneOhm Cdiff Assay demonstrates BD's ongoing commitment to develop a broad range of products that can help prevent healthcare-associated infections (HAIs). BD provides molecular tests for key pathogens associated with HAIs, including methicillin-resistant Staphylococcus aureus (MRSA), methicillin-susceptible Staphylococcus aureus, vancomycin-resistant Enterococci, and now Clostridium difficile.'

In the United Kingdom, Clostridium difficile infections have risen 40 percent in the last three years, infecting eight times as many patients as MRSA and killing twice as many. In the USA annually, an estimated 500,000 people are hospitalised and more than 28,000 die from CDI. The average length of stay for a CDI patient is nearly three times longer than the average patient and excess healthcare costs exceed $1 billion. US rates of CDI continue to increase, driven by a hypervirulent strain known as BI/NAP1/027. This dangerous strain has now been isolated in at least 38 states, Canada and 14 European countries.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 ProHealthServiceZone.com
Netgains Logo